冠心病介入治疗术后早期P2Y12抑制剂单药治疗的进展

Mono-antiplatelet Therapy with P2Y12 Inhibitor Alone in Patients with Coronary Artery Heart Disease Undergoing Percutaneous Coronary Intervention

双联抗血小板治疗是冠心病患者经皮冠脉介入术后的标准抗栓方案,对预防血栓并发症和改善心血管结局具有重要作用。近年来,多项研究证实经皮冠脉介入术后短程双联抗血小板治疗安全有效,而阿司匹林引发的出血风险及其危害日益受到重视。基于此,研究者们提出了经皮冠脉介入术后早期P 2Y 12抑制剂单药治疗的新策略,并证实该方案具有良好的抗栓疗效及安全性。现对该领域的研究进展及其临床意义进行综述。

Dual antiplatelet therapy(DAPT)is the standard antithrombotic therapy after percutaneous coronary intervention(PCI)and plays a pivotal role in preventing thromboembolic events and improving prognosis.The efficacy of the short duration of DAPT after PCI has been confirmed,while the risk of aspirin-related bleeding is getting more and more attention.Recently,a novel single antiplatelet strategy after short DAPT with P 2Y 12 inhibitor alone has been proposed and proved to be effective and safe after PCI.This article reviews the progress and clinical implication of the single antiplatelet therapy with P 2Y 12 inhibitor.